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Lymphoproliferative disorders (LPDs) are generally caused by uncontrolled 
B-cell proliferation induced by the Epstein-Barr virus (EBV) in the setting of 
impaired EBV-specific T-cell immunity, particularly when there is 
pharmacological immunosuppression including Anti-thymocyte globulin 
(ATG).  We herein present an unusual case of EBV associated with LPD 
(EBV-LPD) in which LPD occurred 3 weeks after the use of rabbit ATG 
administered for severe hepatitis-associated AA, and he died of fulminant 
leukemic lymphoma five days after the onset.  We also review the pertinent 
literature about EBV-LPD after immunosuppressive therapy, and document 




Epstein-Barr virus (EBV) associated Lymphoproliferative disorders (LPD) is 
becoming a serious problem with a recent increase in the number of patients 
with immunodeficiency.  In particular, patients who have undergone 
allogeneic hematopoietic stem cell transplantation (HSCT) are predisposed 
to EBV infection or reactivation and development of EBV-related diseases [1].  
EBV monitoring is generally recommended for high risk patients such as 
HSCT recipients of HLA mismatched donors, and patients receiving 
Anti-thymocyte globulin (ATG) after HSCT.  The early detection of EBV 
reactivation would make it possible to perform preemptive therapy with 
rituximab if necessary, thus preventing the proliferation of EBV infected 
B-cells and the evolution of B-cell lymphoma.   
Acquired severe aplastic anemia (SAA) is a rare disease defined by 
peripheral blood pancytopenia associated with hypocellularity of bone 
marrow [2].  Because bone marrow failure is thought to result from an 
immune-mediated mechanism, immunosuppressive therapy (IST) is the 
treatment of choice in patients without a suitable donor for HSCT.  IST 
including ATG and cyclosporine A (CsA) is the most effective treatment for 
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SAA [3].  Several studies have shown that the use of ATG increases the 
frequency of EBV reactivation and the risk of EBV-LPD [4].  However, this 
risk has not yet been sufficiently documented in patients treated with ATG 
for SAA.  It is also unclear whether EBV-viral load monitoring during IST 
for SAA and subsequent preemptive therapy are beneficial [5-6].   
We herein report an unusual case of fulminant EBV-LPD that occurred in a 
patient as a form of leukemic lymphoma three weeks after the first 





A 54-year-old male presented to the hospital with a 3 week history of general 
malaise and loss of appetite.  He showed jaundice and had severely 
deranged liver function tests, with a total bilirubin of 5.5 mg/dL (0.3-1.2 
mg/dL, direct fraction: 3.1 mg/dL)), alkaline phosphatase (ALP) of 536 IU/L 
(115-359 IU/L), aspartate aminotransferase (AST) of 1021 IU/L (13-33 IU/L), 
alanine aminotransferase (ALT) of 2718 IU/L (8-42 IU/L) and gamma 
glutaryl transpeptidase (GGTP) of 288 IU/L (10-47 IU/L).  His blood tests 
showed a platelet count of 12109/L, hemoglobin (Hb) of 13.1 g/dL and a 
white blood cell count (WBC) of 1.4109/L, with neutrophils of 0.7109/L.  
The absolute counts of CD4 and CD8 positive T-cells were 0.2109/L and 
0.1109/L.  A blood film showed leukopenia and thrombocytopenia, with no 
abnormal morphology.  There was no history of recent travel, blood 
transfusions, and the use of medications or excess alcohol consumption.  
Subsequent investigations showed no evidence of a viral etiology.  Hepatitis 
A virus IgM, Hepatitis B virus (HBV) Ag, hepatitis B core IgM, HCV 
antibody, hepatitis C RNA PCR, hepatitis E virus IgM and IgG were all 
negative.  The HBs antibody was positive, but HBV-PCR was negative.  
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The cytomegalovirus (CMV)-IgG was positive and CMV-IgM was weakly 
positive.  His anti-EBV antibody titers were VCA IgG positive, VCA IgM 
negative, EA negative, and EBNA positive.  Parvovirus B19 IgM and IgG 
serology were negative.  The patient was also negative for HIV antibodies.  
The bone marrow was severely hypocellular, which was consistent with AA.  
Immunophenotyping of bone marrow cells was normal, and there was no 
evidence of paroxysmal nocturnal hemoglobinuria.  A liver biopsy was not 
performed due to the presence of severe thrombocytopenia.  We diagnosed 
him with hepatitis-associated AA.  ATG therapy was put on hold until his 
liver function tests improved, but his pancytopenia progressed without 
normalization of his jaundice.  Rabbit ATG was started three weeks after 
admission at a dose of 3.75 mg/kg on days 1-5, and CsA at a dose of 3 mg/kg 
with methylprednisolone, which resulted in a rapid improvement in his liver 
function.  He was further treated with prednisolone for prophylaxis of 
serum sickness, with normalization of liver function tests, but his 
hematological data still showed pancytopenia.   
Three weeks after the administration of ATG, the patient developed a 
persistent high fever, which was refractory to antibiotics and antifungal 
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agents.  Moreover, his liver function tests worsened, including a total 
bilirubin of 1.9 mg/dL, AST of 408 IU/L, ALT of 577 IU/L, GTP of 779 IU/L, 
and ALP of 848 IU/L.  Blood tests showed a platelet count of 15109/L, Hb of 
9.2 g/dL and a WBC of 7.5109/L.  A peripheral blood smear revealed an 
increased number of lymphocytes (2.0 x 109/L), but no apparent 
hemophagocytic findings.  The phenotype of the atypical lymphocytes was 
CD3, CD10, CD19, CD20 and IgG light chain lambda.  The serum 
ferritin (199,770 ng/mL) level was also markedly elevated.  Based on these 
clinical signs, laboratory data, and the use of ATG, EBV-LPD was highly 
suspected.  The administration of rituximab was considered, but severe 
metabolic acidosis and cardio-respiratory failure developed the evening after 
EBV-LPD was diagnosed and the patient died of the LPD on the following 
day.   
The belated results of the peripheral blood EBV-DNA (3.3×106 copies/ 
106WBC) and pathological examination from liver biopsy (demonstrating an 
increase in CD20 positive lymphocytes that were positive for EBV-encoded 
mRNA (EBER) by in situ hybridization) confirmed the diagnosis of 
EBV-associated diffuse large B-cell lymphoma (DLBCL).  Infiltration of the 
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lymphoma was also detected in his bone marrow.  We analyzed the patient’s 
peripheral plasma EBV-DNA retrospectively.  His plasma showed an 
elevation of the EBV-viral load to 700 copies/mL for the first time at 7 days 
before the onset of pyrexia, and the EBV-viral load rapidly increased within 




We herein describe the occurrence of fulminant EBV-LPD that was 
diagnosed following a sharp increase in the atypical B cell count in the 
peripheral blood three weeks after IST for hepatitis-associated AA.  The 
patient died of cardio-respiratory failure associated with severe lactic 
acidosis due to rapidly progressive lymphoma.  Lactic acidosis in association 
with hematologic malignancies normally shows an extremely poor prognosis 
[7].   
It is well documented that EBV is an important complication of prolonged 
immunodeficiency.  All patients who have a limited number of circulating T 
cells and retain B cells are at risk of developing EBV reactivation, as the 
interplay among EBV replication, latency, and immune control is not as 
balanced as in the healthy host.  When there is pharmacological 
immunosuppression, EBV reactivation can lead to LPD because T cell 
function is severely impaired and B cells can evade T cell attack and expand.  
This is particularly common in patients undergoing HSCT with an 
ATG-containing conditioning regimen [4].   
Treatment with ATG combined with CsA is the standard therapeutic 
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approach to SAA.  Scheinberg et al. showed the risk of EBV disease in 
patients treated with ATG for AA to be low [5].  In their study of 78 patients 
with SAA who had received four different immunosuppressive regimens, 
including ATG, even though EBV reactivation occurred in most patients, 
none developed symptomatic EBV-LPD.  To determine the incidence of 
clinically-significant EBV-LPD, we searched Medline for published articles 
about LPD after IST for AA.  As shown in Table 1, a total of 8 cases of LPD 
that occurred after IST have been reported [6,8-14].   
Viola et al. recently reported a patient who developed LPD 1 month after 
the use of horse ATG for the treatment of SAA [14].  Although the interval 
between ATG therapy and the onset of LPD in this case was short, similar to 
our case, he had received chemotherapy and autologous HSCT for the 
treatment of NHL 3 years prior to the ATG therapy, both of which may have 
predisposed the patient to develop LPD.   
Wondergem et al. described a patient who received a higher dose rabbit 
ATG for SAA after failing to respond to horse ATG.  The patient then 
developed life-threatening EBV-related lymphoma [6].  In our patient, LPD 
occurred after his first ATG therapy.  To the best of our knowledge, this is 
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the first report of an EBV-related DLBCL in a patient treated with a single 
course of rabbit ATG.   
Recently, the viral load has been shown to be a significant predictor of 
EBV related post-transplant lymphoproliferative disorders [15-16], and early 
treatment with an anti-CD20 antibody is recommended as preemptive 
therapy in patients undergoing an alternative donor transplant [1].  
Because of the rapid clinical course of EBV-LPD, immediate treatment is 
crucial to reduce mortality [6].  No lymphocytosis or pyrexia was observed 
when the EBV-DNA level began to increase in our patient, (Figure 1).  
Preemptive therapy with rituximab may improve the treatment outcome of 
EBV-LPD, not only after HSCT [17], but also after IST for SAA.  However, 
the EBV copy number in the plasma of the current patient at day 19 of ATG 
therapy, 1 week before the onset of pyrexia, was 700 copies/mL, but it 
increased by more than 20 fold on day 24 (16,000 copies/mL).  Therefore, 
once a week screening of EBV would have been useless for this patient.  The 
prompt examination of blood for EBV copy number in response to clinical 
signs such as pyrexia may be more practical than surveillance for 
appropriately starting rituximab.  The preventive administration of 
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rituximab would be a possible option for AA patients with a high risk of 
developing EBV-LPD.   
Several risk factors for susceptibility to EBV-related lymphoma have been 
identified.  Dierksheide et al. showed that an IFN-gamma polymorphism 
affects a likelihood of EBV reactivation [18].  Genotyping of the IFN-gamma 
gene may be useful for identifying patients at greater risk of developing 
EBV-LPD.  The percentage of CD4 T cells in hepatitis-associated AA 
patients is reported to be significantly lower than that in non- 
hepatitis-associated AA patients [19].  Therefore, the presence of 
hepatitis-associated AA may have predisposed our patient to developing 
EBV-LPD.   
The short time interval between ATG treatment and diagnosis and the 
fulminant course of EBV-LPD in our case and in the case reported by Viola et 
al. may be related to the profound immunosuppressive state associated with 
hepatitis and precedent chemotherapy in the cases.   
The present case indicates that fulminant EBV-associated lymphoma can 
occur in patients with AA even after a single course of rabbit ATG therapy.  
Close monitoring of the EBV-viral load is therefore prerequisite for rabbit 
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Table 1. Reports of Lymphoproliferative disorders (LPD) after 




ALL  acute lymphoblastic leukemia, DLBCL = diffuse large B-cell 
lymphoma, EBV = Epstein-Barr virus, ATG = anti-thymocyte globulin, hATG 
 horse ATG, rATG  rabbit ATG, CsA = cyclosporine, PSL  prednisolone
References Case Type of LPD Immunosuppression 
Dorr, 1996 17 F Lymphoma ATG, CsA 
Sarangi, 1999 22 M T-ALL CsA 
Takeuchi, 2000 54 F B-ALL CsA, PSL etc 
Hirose, 2001 24 M T-ALL CsA 
Calistri, 2006 38 M Infectious mononucleosis rATG, CsA, M-PSL  hATG 
Wondergem, 2008 42 F EBV()DLBCL hATG, CsA  rATG, CsA 
Suzuki, 2009 63 F EBV()DLBCL ATG, CsA 
Viola, 2010 55 M EBV() plasma cell hyperplasia hATG 




Figure 1. The changes in plasma Epstein-Barr virus (EBV)-DNA and his 
body temperature.  Open and closed circles represent EBV-negative and 
positive states.  Increase in EBV-DNA was observed two weeks after 
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